CStone Pharmaceuticals Future Growth
Future criteria checks 5/6
CStone Pharmaceuticals is forecast to grow earnings and revenue by 56.9% and 27.2% per annum respectively. EPS is expected to grow by 54.6% per annum. Return on equity is forecast to be -37.9% in 3 years.
Key information
56.9%
Earnings growth rate
54.6%
EPS growth rate
Biotechs earnings growth | 35.4% |
Revenue growth rate | 27.2% |
Future return on equity | -37.9% |
Analyst coverage | Low |
Last updated | 03 Apr 2024 |
Recent future growth updates
Recent updates
Lacklustre Performance Is Driving CStone Pharmaceuticals' (HKG:2616) 28% Price Drop
Mar 04Benign Growth For CStone Pharmaceuticals (HKG:2616) Underpins Stock's 25% Plummet
Jan 18The Market Doesn't Like What It Sees From CStone Pharmaceuticals' (HKG:2616) Revenues Yet As Shares Tumble 26%
Oct 04Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?
Oct 03Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?
Oct 20Is CStone Pharmaceuticals (HKG:2616) Using Too Much Debt?
Dec 17Analysts Expect Breakeven For CStone Pharmaceuticals (HKG:2616) Before Long
Apr 29What Kind Of Shareholders Own CStone Pharmaceuticals (HKG:2616)?
Mar 02Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,186 | 89 | N/A | N/A | 1 |
12/31/2025 | 978 | -159 | N/A | N/A | 2 |
12/31/2024 | 845 | -454 | N/A | N/A | 2 |
12/31/2023 | 464 | -367 | -437 | -589 | N/A |
9/30/2023 | 472 | -559 | -487 | -548 | N/A |
6/30/2023 | 481 | -750 | -539 | -510 | N/A |
3/31/2023 | 481 | -827 | -626 | -561 | N/A |
12/31/2022 | 481 | -903 | -714 | -612 | N/A |
9/30/2022 | 454 | -1,205 | -966 | -842 | N/A |
6/30/2022 | 426 | -1,508 | -1,219 | -1,072 | N/A |
3/31/2022 | 335 | -1,714 | -1,426 | -1,278 | N/A |
12/31/2021 | 244 | -1,920 | -1,633 | -1,484 | N/A |
9/30/2021 | 681 | -1,622 | -1,241 | -1,103 | N/A |
6/30/2021 | 1,118 | -1,324 | -848 | -722 | N/A |
3/31/2021 | 1,079 | -1,272 | -714 | -615 | N/A |
12/31/2020 | 1,039 | -1,221 | -580 | -508 | N/A |
9/30/2020 | 519 | -1,482 | -971 | -920 | N/A |
6/30/2020 | -2 | -1,744 | -1,362 | -1,333 | N/A |
3/31/2020 | -1 | -1,906 | -1,227 | -1,207 | N/A |
12/31/2019 | N/A | -2,069 | -1,091 | -1,081 | N/A |
9/30/2019 | 11 | -1,688 | -907 | -898 | N/A |
6/30/2019 | 12 | -1,246 | -706 | -699 | N/A |
3/31/2019 | 12 | -858 | -752 | -745 | N/A |
12/31/2018 | 13 | -470 | -799 | -791 | N/A |
9/30/2018 | 13 | -336 | -693 | -679 | N/A |
12/31/2017 | 10 | -107 | -253 | -240 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2616 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: 2616 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 2616 is expected to become profitable in the next 3 years.
Revenue vs Market: 2616's revenue (27.2% per year) is forecast to grow faster than the Hong Kong market (7.7% per year).
High Growth Revenue: 2616's revenue (27.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2616 is forecast to be unprofitable in 3 years.